EMORY UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1836-12-10

Employees: 10K

Market Cap: -

Website: http://www.emory.edu

Clinical Trials

Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision

Phase 2

Terminated

Conditions: Pancreatic Neoplasms
Pancreatic Cancer

Interventions: Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2010-08-25

Last Posted Date: 2016-09-28

Lead Sponsor: Emory University

Target Recruit Count: 25

Registration Number: NCT01188109

Locations: 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States

Effects of Dietary Fructose Reduction in Children With Hepatic Steatosis

Not Applicable

Completed

Conditions: Non-alcoholic Fatty-liver Disease

Interventions: Dietary Supplement: Fructose Drink
Dietary Supplement: Glucose Drink

First Posted Date: 2010-08-25

Last Posted Date: 2013-11-21

Lead Sponsor: Emory University

Target Recruit Count: 53

Registration Number: NCT01188083

Locations: 🇺🇸
Emory Children's Center, Atlanta, Georgia, United States

The Effectiveness of Lubiprostone in Constipated Diabetics

Phase 4

Completed

Conditions: Constipation
Diabetes

Interventions: Drug: Placebo
Drug: Lubiprostone

First Posted Date: 2010-07-27

Last Posted Date: 2016-03-15

Lead Sponsor: Emory University

Target Recruit Count: 121

Registration Number: NCT01170039

Locations: 🇺🇸
Atlanta Veterans Administration Hospital, Atlanta, Georgia, United States
🇺🇸
The Emory Clinic, Atlanta, Georgia, United States

Oxidative Stress Markers and Cardiac Resynchronization Therapy (CRT) Outcomes

Not Applicable

Terminated

Conditions: Congestive Heart Failure

Interventions: Device: CRT Therapy

First Posted Date: 2010-06-28

Last Posted Date: 2013-09-19

Lead Sponsor: Emory University

Target Recruit Count: 5

Registration Number: NCT01151553

Alteration in Timing of Plerixafor Administration

Phase 2

Completed

Conditions: Autologous Transplantation

Interventions: Drug: Plerixafor

First Posted Date: 2010-06-24

Last Posted Date: 2013-12-13

Lead Sponsor: Emory University

Target Recruit Count: 34

Registration Number: NCT01149863

Locations: 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States

Misoprostol Prior to Intrauterine Device (IUD) Insertion in Nulliparous Women

Not Applicable

Completed

Conditions: Contraception

Interventions: Drug: Placebo
Drug: Misoprostol

First Posted Date: 2010-06-22

Last Posted Date: 2018-01-12

Lead Sponsor: Emory University

Target Recruit Count: 78

Registration Number: NCT01147497

Locations: 🇺🇸
The Emory Clinic, Atlanta, Georgia, United States

Effects of Low-density Lipoprotein (LDL) Apheresis on Inflammatory and Lipid Markers

Completed

Conditions: Familial Hypercholesterolemia

Interventions: Procedure: LDL Apheresis

First Posted Date: 2010-06-07

Last Posted Date: 2013-12-17

Lead Sponsor: Emory University

Target Recruit Count: 8

Registration Number: NCT01138371

Locations: 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States

Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Phase 2

Withdrawn

Conditions: Primary Peritoneal
Fallopian Tube Neoplasms
Ovarian Cancer

Interventions: Drug: Gemcitabine/Bevacizumab

First Posted Date: 2010-05-26

Last Posted Date: 2013-12-20

Lead Sponsor: Emory University

Registration Number: NCT01131039

Optimal Coronary Sinus Lead Implantation Using Intracardiac Impedography and Magnetic Resonance Imaging

Not Applicable

Completed

Conditions: Heart Failure, Systolic
Left Bundle Branch Block

Interventions: Procedure: Cardiac Resynchronization Therapy (CRT) implantation

First Posted Date: 2010-05-24

Last Posted Date: 2015-01-21

Lead Sponsor: Emory University

Target Recruit Count: 38

Registration Number: NCT01129635

Locations: 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States

Phase I Chemoprevention Trial With Green Tea Polyphenon E & Erlotinib in Patients With Premalignant Lesions of the Head & Neck

Phase 1

Completed

Conditions: Cancer of Head and Neck
Neoplasms, Head and Neck

Interventions: Drug: Erlotinib
Dietary Supplement: Green Tea Polyphenon E

First Posted Date: 2010-05-05

Last Posted Date: 2018-12-05

Lead Sponsor: Emory University

Target Recruit Count: 25

Registration Number: NCT01116336

Locations: 🇺🇸
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy